ClinicalTrials.gg
CompletedNCT03575104Updated Mar 25, 2022Results posted

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

A Phase 3 interventional study of Daridorexant and Placebo in Insomnia Disorder, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 86 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-25.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
924
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders — 6 open to participants now, 6 under way, none of them phase 3. daridorexant · Sleep Initiation and Maintenance Disorders.

Enrollment
3rd of 16
924 · median 165
Started
2018
with 2 others
Phase 3
5 of 16
none open now
Registered
4th of 16
by date
Lead sponsor
8 of 16
Idorsia Pharmaceuticals Ltd.

Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, this one is the 3rd largest by enrollment, is one of 3 that started in 2018, is one of 5 in phase 3, and was the 4th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

6 of the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About daridorexant

daridorexant: first FDA approval 2022 (QUVIVIQ), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

The main purpose of this study is to assess efficacy and safety of ACT-541468 (daridorexant) in adult and elderly subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

03

Conditions studied

  • Insomnia Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to any study-mandated procedure;
  • Male or female aged ≥ 18 years;
  • Insomnia disorder according to criteria;
  • Insomnia Severity Index score ≥ 15;
  • Insufficient sleep quantity as collected subjectively in the sleep diary and validated objectively by polysomnography;
  • Women of must have a negative and urine pregnancy test and use the scheme up to at least 30 days after last study treatment intake.

Exclusion criteria

Exclusion Criteria:

  • below 18.5 or above 40.0 kg/m2;
  • Any lifetime history of of related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement (REM) behavior disorder, narcolepsy, or apnea/hypopnea;
  • Cognitive behavioral therapy (CBT) only allowed if, the treatment started at least 1 month prior to Visit 3 and the subject agrees to continue this CBT throughout the study;
  • Self-reported usual daytime napping ≥ 1 hour per day and ≥ 3 days per week;
  • Acute or unstable psychiatric conditions diagnosed by the Mini International Neuropsychiatric Interview;
  • (MMSE) score \< 25 in subjects ≥ 50 years;
  • For female subjects: pregnant, lactating or planning to become pregnant during projected duration of the study;
  • History or clinical evidence of any disease or medical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the study assessments.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
924 participants (actual)

Study arms

  • Experimental
    Daridorexant 10 mg

    Drug: Daridorexant

  • Experimental
    Daridorexant 25 mg

    Drug: Daridorexant

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Daridorexant will be administered as tablets, orally, once daily in the evening.

  • OtherPlacebo

    Matching placebo will be administered as tablets, orally, once daily in the evening.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance)

    "Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.

    Time frame: From baseline to Month 1 (i.e. for up to 1 month)

  2. Change From Baseline to Month 3 in Wake After Sleep Onset (WASO)

    "Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.

    Time frame: From baseline to Month 3 (i.e. for up to 3 months)

  3. Change From Baseline to Month 1 in Latency to Persistent Sleep (LPS) (Sleep Onset)

    "Latency to Persistent Sleep" is the time from start of recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-awake, i.e., epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep) or REM, as determined by polysomnography.

    Time frame: From baseline to Month 1 (i.e. for up to 1 month)

  4. Change From Baseline to Month 3 in Latency to Persistent Sleep (LPS)

    "Latency to Persistent Sleep" is the time from start of recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-awake, i.e., epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep) or REM, as determined by polysomnography.

    Time frame: From baseline to Month 3 (i.e. for up to 3 months)

Secondary outcomes

  1. Change From Baseline to Month 1 in the Subjective Total Sleep Time (sTST)

    "Subjective Total Sleep Time" is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in the subjective Total Sleep Time. A negative change from baseline indicates a decrease in subjective Total Sleep Time.

    Time frame: From baseline to Month 1 (i.e. for up to 1 month)

  2. Change From Baseline to Month 3 in the Subjective Total Sleep Time (sTST)

    Subjective Total Sleep Time is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in the subjective Total Sleep Time. A negative change from baseline indicates a decrease in subjective Total Sleep Time.

    Time frame: From baseline to Month 3 (i.e. for up to 3 months)

  3. Change From Baseline to Month 1 in Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Sleepiness Domain Score

    The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) is a validated patient reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., sleepiness, mood, and alert/cognition) reflecting daytime impairment of insomnia. The IDSIQ sleepiness domain has 4 items, and the domain score ranges from 0 to a maximum of 40, where a higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

    Time frame: From baseline to Month 1 (i.e. for up to 1 month)

  4. Change From Baseline to Month 3 in IDSIQ Sleepiness Domain Score

    The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) is a validated patient reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., sleepiness, mood, and alert/cognition) reflecting daytime impairment of insomnia. The IDSIQ sleepiness domain has 4 items, and the domain score ranges from 0 to a maximum of 40, where a higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

    Time frame: From baseline to Month 3 (i.e. for up to 3 months)

07

Results

Posted Mar 25, 2022

Participant flow

Participant flow — Overall Study
MilestoneDaridorexant 10 mgDaridorexant 25 mgPlacebo
Started307309308
Completed283280286
Not completed242922
Withdrew: Adverse event434
Withdrew: Withdrawal by subject131611
Withdrew: Other reasons686
Withdrew: Lost to follow-up121

Outcome measures

PrimaryChange From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance)

"Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.

Time frame:
From baseline to Month 1 (i.e. for up to 1 month)
Reported as:
Least squares mean · minutes
Change From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance)
minutesDaridorexant 10 mgDaridorexant 25 mgPlacebo
Change From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance)-15.31 (-19.531 to -11.087)-24.19 (-28.466 to -19.911)-12.57 (-16.817 to -8.323)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = 0.0001 (Mixed effects model for repeated measures: change from baseline in WASO = baseline WASO + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -11.62 · 95% CI -17.604 to -5.633Hypothesis testing result: threshold for significance p = 0.025; statistically significant = YES
  • Daridorexant 10 mg vs Placebo · Mixed Models Analysis · p = 0.3669 (Mixed effects model for repeated measures: change from baseline in WASO = baseline WASO + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -2.74 · 95% CI -8.693 to 3.215Hypothesis testing result: threshold for significance p = 0.00977; statistically significant = NO
PrimaryChange From Baseline to Month 3 in Wake After Sleep Onset (WASO)

"Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.

Time frame:
From baseline to Month 3 (i.e. for up to 3 months)
Reported as:
Least squares mean · minutes
Change From Baseline to Month 3 in Wake After Sleep Onset (WASO)
minutesDaridorexant 10 mgDaridorexant 25 mgPlacebo
Change From Baseline to Month 3 in Wake After Sleep Onset (WASO)-15.95 (-20.734 to -11.165)-24.25 (-29.021 to -19.474)-14.00 (-18.756 to -9.241)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = 0.0028 (Mixed effects model for repeated measures: change from baseline in WASO = baseline WASO + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -10.25 · 95% CI -16.95 to -3.548Hypothesis testing result: threshold for significance p = 0.01563; statistically significant = YES
  • Daridorexant 10 mg vs Placebo · Mixed Models Analysis · p = 0.5686 (Mixed effects model for repeated measures: change from baseline in WASO = baseline WASO + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -1.95 · 95% CI -8.666 to 4.764Hypothesis testing result: threshold for significance p = 0; statistically significant = NO
PrimaryChange From Baseline to Month 1 in Latency to Persistent Sleep (LPS) (Sleep Onset)

"Latency to Persistent Sleep" is the time from start of recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-awake, i.e., epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep) or REM, as determined by polysomnography.

Time frame:
From baseline to Month 1 (i.e. for up to 1 month)
Reported as:
Least squares mean · minutes
Change From Baseline to Month 1 in Latency to Persistent Sleep (LPS) (Sleep Onset)
minutesDaridorexant 10 mgDaridorexant 25 mgPlacebo
Change From Baseline to Month 1 in Latency to Persistent Sleep (LPS) (Sleep Onset)-22.62 (-26.733 to -18.503)-26.46 (-30.626 to -22.292)-20.01 (-24.148 to -15.875)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = 0.0303 (Mixed effects model for repeated measures: change from baseline in LPS = baseline LPS + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -6.45 · 95% CI -12.282 to -0.614Hypothesis testing result: threshold for significance p = 0.025; statistically significant = NO
  • Daridorexant 10 mg vs Placebo · Mixed Models Analysis · p = 0.3782 (Mixed effects model for repeated measures: change from baseline in LPS = baseline LPS + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -2.61 · 95% CI -8.41 to 3.197Hypothesis testing result: threshold for significance p = 0.00195; statistically significant = NO
PrimaryChange From Baseline to Month 3 in Latency to Persistent Sleep (LPS)

"Latency to Persistent Sleep" is the time from start of recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-awake, i.e., epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep) or REM, as determined by polysomnography.

Time frame:
From baseline to Month 3 (i.e. for up to 3 months)
Reported as:
Least squares mean · minutes
Change From Baseline to Month 3 in Latency to Persistent Sleep (LPS)
minutesDaridorexant 10 mgDaridorexant 25 mgPlacebo
Change From Baseline to Month 3 in Latency to Persistent Sleep (LPS)-23.09 (-27.600 to -18.571)-28.91 (-33.413 to -24.399)-19.89 (-24.384 to -15.405)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = 0.0053 (Mixed effects model for repeated measures: change from baseline in LPS = baseline LPS + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -9.01 · 95% CI -15.339 to -2.684Hypothesis testing result: threshold for significance p = 0.00313; statistically significant = NO
  • Daridorexant 10 mg vs Placebo · Mixed Models Analysis · p = 0.3233 (Mixed effects model for repeated measures: change from baseline in LPS = baseline LPS + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -3.19 · 95% CI -9.528 to 3.146Hypothesis testing result: threshold for significance p = 0; statistically significant = NO
SecondaryChange From Baseline to Month 1 in the Subjective Total Sleep Time (sTST)

"Subjective Total Sleep Time" is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in the subjective Total Sleep Time. A negative change from baseline indicates a decrease in subjective Total Sleep Time.

Time frame:
From baseline to Month 1 (i.e. for up to 1 month)
Reported as:
Least squares mean · minutes
Change From Baseline to Month 1 in the Subjective Total Sleep Time (sTST)
minutesDaridorexant 10 mgDaridorexant 25 mgPlacebo
Change From Baseline to Month 1 in the Subjective Total Sleep Time (sTST)41.01 (35.439 to 46.584)43.77 (38.136 to 49.412)27.64 (22.015 to 33.274)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = <.0001 (Hypothesis testing result: threshold for significance p = 0.0125; statistically significant = YES) · Ls mean difference to placebo: 16.13 · 95% CI 8.224 to 24.035
  • Daridorexant 10 mg vs Placebo · Mixed Models Analysis · p = = 0.0009 (Mixed effects model for repeated measures: change from baseline in sTST = baseline sTST + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: 13.37 · 95% CI 5.507 to 21.226Hypothesis testing result: threshold for significance p = 0; statistically significant = NO
SecondaryChange From Baseline to Month 3 in the Subjective Total Sleep Time (sTST)

Subjective Total Sleep Time is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in the subjective Total Sleep Time. A negative change from baseline indicates a decrease in subjective Total Sleep Time.

Time frame:
From baseline to Month 3 (i.e. for up to 3 months)
Reported as:
Least squares mean · minutes
Change From Baseline to Month 3 in the Subjective Total Sleep Time (sTST)
minutesDaridorexant 10 mgDaridorexant 25 mgPlacebo
Change From Baseline to Month 3 in the Subjective Total Sleep Time (sTST)50.70 (44.398 to 57.008)56.18 (49.812 to 62.547)37.12 (30.776 to 43.464)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = <.0001 (Mixed effects model for repeated measures: change from baseline in sTST = baseline sTST + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: 19.06 · 95% CI 10.125 to 27.994Hypothesis testing result: threshold for significance p = 0.00781; statistically significant = YES
  • Daridorexant 10 mg vs Placebo · Mixed Models Analysis · p = = 0.0028 (Mixed effects model for repeated measures: change from baseline in sTST = baseline sTST + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: 13.58 · 95% CI 4.691 to 22.475Hypothesis testing result: threshold for significance p = 0; statistically significant = NO
SecondaryChange From Baseline to Month 1 in Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Sleepiness Domain Score

The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) is a validated patient reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., sleepiness, mood, and alert/cognition) reflecting daytime impairment of insomnia. The IDSIQ sleepiness domain has 4 items, and the domain score ranges from 0 to a maximum of 40, where a higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

Time frame:
From baseline to Month 1 (i.e. for up to 1 month)
Reported as:
Least squares mean · Scores on a scale
Change From Baseline to Month 1 in Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Sleepiness Domain Score
Scores on a scaleDaridorexant 10 mgDaridorexant 25 mgPlacebo
Change From Baseline to Month 1 in Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Sleepiness Domain Score-3.18 (-3.763 to -2.599)-3.51 (-4.096 to -2.917)-2.75 (-3.340 to -2.163)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = = 0.0733 (Mixed effects model for repeated measures: change from baseline in IDSIQ sleepiness domain score = baseline IDSIQ sleepiness domain score + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -0.75 · 95% CI -1.581 to 0.071Hypothesis testing result: threshold for significance p = 0.00625; statistically significant = NO
  • Daridorexant 10 mg vs Placebo · Mixed Models Analysis · p = = 0.3048 (Mixed effects model for repeated measures: change from baseline in IDSIQ sleepiness domain score = baseline IDSIQ sleepiness domain score + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -0.43 · 95% CI -1.251 to 0.392Hypothesis testing result: threshold for significance p = 0; statistically significant = NO
SecondaryChange From Baseline to Month 3 in IDSIQ Sleepiness Domain Score

The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) is a validated patient reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., sleepiness, mood, and alert/cognition) reflecting daytime impairment of insomnia. The IDSIQ sleepiness domain has 4 items, and the domain score ranges from 0 to a maximum of 40, where a higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

Time frame:
From baseline to Month 3 (i.e. for up to 3 months)
Reported as:
Least squares mean · Scores on a scale
Change From Baseline to Month 3 in IDSIQ Sleepiness Domain Score
Scores on a scaleDaridorexant 10 mgDaridorexant 25 mgPlacebo
Change From Baseline to Month 3 in IDSIQ Sleepiness Domain Score-4.75 (-5.437 to -4.056)-5.27 (-5.964 to -4.569)-4.01 (-4.705 to -3.322)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = = 0.0120 (Mixed effects model for repeated measures: change from baseline in IDSIQ sleepiness domain score = baseline IDSIQ sleepiness domain score + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -1.25 · 95% CI -2.230 to -0.276Hypothesis testing result: threshold for significance p = 0.00391; statistically significant = NO
  • Daridorexant 10 mg vs Placebo · Mixed Models Analysis · p = = 0.1393 (Mixed effects model for repeated measures: change from baseline in IDSIQ sleepiness domain score = baseline IDSIQ sleepiness domain score + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -0.73 · 95% CI -1.706 to 0.239Hypothesis testing result: threshold for significance p = 0; statistically significant = NO
Post-hocChange From Baseline to Month 1 in Log-transformed LPS (LSGM Ratio to Baseline)

Post-hoc analyses were performed using log-transformed LPS data, as the LPS values at baseline more closely resembled a log-normal distribution (skewed to the right) than a normal distribution.

Time frame:
From baseline to Month 1 (i.e. for up to 1 month)
Reported as:
Geometric least squares mean · minutes
Change From Baseline to Month 1 in Log-transformed LPS (LSGM Ratio to Baseline)
minutesDaridorexant 10 mgDaridorexant 25 mgPlacebo
Change From Baseline to Month 1 in Log-transformed LPS (LSGM Ratio to Baseline)0.59 (0.54 to 0.64)0.50 (0.46 to 0.55)0.63 (0.58 to 0.69)
Statistical analysis
  • Daridorexant 10 mg vs Placebo · Mixed Models Analysis · p = 0.2506 (Mixed effects model for repeated measures: log(value/baseline) = log(baseline) + age group(\< 65; ≥ 65 years) + treatment + visit + treatment x visit + log(baseline) x visit.) · Ls mean difference to placebo: 0.93 · 95% CI 0.82 to 1.05
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = 0.0004 (Mixed effects model for repeated measures: log(value/baseline) = log(baseline) + age group(\< 65; ≥ 65 years) + treatment + visit + treatment x visit + log(baseline) x visit.) · Ls mean difference to placebo: 0.80 · 95% CI 0.71 to 0.91
Post-hocChange From Baseline to Month 3 in Log-transformed LPS (LSGM Ratio to Baseline)

Post-hoc analyses were performed using log-transformed LPS data, as the LPS values at baseline more closely resembled a log-normal distribution (skewed to the right) than a normal distribution.

Time frame:
From baseline to Month 3 (i.e. for up to 3 month)
Reported as:
Geometric least squares mean · minutes
Change From Baseline to Month 3 in Log-transformed LPS (LSGM Ratio to Baseline)
minutesDaridorexant 10 mgDaridorexant 25 mgPlacebo
Change From Baseline to Month 3 in Log-transformed LPS (LSGM Ratio to Baseline)0.56 (0.51 to 0.61)0.48 (0.43 to 0.52)0.58 (0.53 to 0.64)
Statistical analysis
  • Daridorexant 10 mg vs Placebo · Mixed Models Analysis · p = 0.5037 (Mixed effects model for repeated measures: log(value/baseline) = log(baseline) + age group(\< 65; ≥ 65 years) + treatment + visit + treatment x visit + log(baseline) x visit.) · Ls mean difference to placebo: 0.96 · 95% CI 0.84 to 1.09
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = 0.0021 (Mixed effects model for repeated measures: log(value/baseline) = log(baseline) + age group(\< 65; ≥ 65 years) + treatment + visit + treatment x visit + log(baseline) x visit.) · Ls mean difference to placebo: 0.81 · 95% CI 0.71 to 0.93

Adverse events

Collected over Treatment-emergent AEs were AEs that started or worsened on or after the DB study treatment start date up to the earlier of 30 days after DB study treatment end date or the date of enrollment in the ID-078A303 extension study. The planned duration of DB treatment was 84 days ± 2 days, i.e., 12 weeks ± 2 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Daridorexant 10 mg0/306 (0%)3/306 (1%)49/306 (16%)
Daridorexant 25 mg0/308 (0%)3/308 (1%)28/308 (9.1%)
Placebo0/306 (0%)4/306 (1.3%)30/306 (9.8%)
Most frequent serious events
Most frequent serious events
EventDaridorexant 10 mgDaridorexant 25 mgPlacebo
Hypertensive crisisVascular disorders0/3060/3081/306
Joint dislocationInjury, poisoning and procedural complications0/3060/3081/306
Meniscus injuryInjury, poisoning and procedural complications0/3060/3081/306
Microvascular coronary artery diseaseCardiac disorders1/3060/3080/306
VertigoEar and labyrinth disorders1/3060/3080/306
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/3060/3081/306
AppendicitisInfections and infestations1/3060/3080/306
HaemoptysisRespiratory, thoracic and mediastinal disorders0/3061/3080/306
Lumbar radiculopathyNervous system disorders0/3061/3080/306
SchizophreniaPsychiatric disorders0/3061/3080/306
Most frequent other events
Most frequent other events
EventDaridorexant 10 mgDaridorexant 25 mgPlacebo
NasopharyngitisInfections and infestations38/30613/30820/306
HeadacheNervous system disorders14/30616/30811/306

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Daridorexant 10 mgDaridorexant 25 mgPlaceboTotal
<=18 years0000
Between 18 and 65 years186188187561
>=65 years121121121363
Age, Continuous
Age, Continuous(years)Daridorexant 10 mgDaridorexant 25 mgPlaceboTotal
Mean57.1 ± 14.056.3 ± 14.456.7 ± 14.156.7 ± 14.2
Sex: Female, Male
Sex: Female, Male(Participants)Daridorexant 10 mgDaridorexant 25 mgPlaceboTotal
Female215218205638
Male9291103286
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Daridorexant 10 mgDaridorexant 25 mgPlaceboTotal
Hispanic or Latino17141647
Not Hispanic or Latino288295290873
Unknown1012
Not permitted as per legislation/regulation1012
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Daridorexant 10 mgDaridorexant 25 mgPlaceboTotal
Black or African American16262971
American Indian or Alaska Native2002
Native Hawaiian or other Pacific Islander0112
Asian14111035
White273271267811
Not permitted as per legislation/regulation1012
Other1001
08

Study locations

86 sites
  • Pulmonary Associates, Pa
    Glendale, Arizona 85306, United States
  • Noble Clinical Research
    Tucson, Arizona 85704, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Core Healthcare Group
    Cerritos, California 90703, United States
  • Artemis Institute For Clinical Research - Riverside
    Riverside, California 92503, United States
  • Pacific Research Network
    San Diego, California 92103, United States
  • Artemis Institute for Clinical Research
    San Marcos, California 92078, United States
  • Santa Monica Clinical Trials
    Santa Monica, California 90404, United States
  • Empire Clinical Research
    Upland, California 91786, United States
  • Innovative Clinical Research
    Lafayette, Colorado 80026, United States
  • Clinical Research of South Florida
    Coral Gables, Florida 33134, United States
  • Fleming Island Center for Clinical Research
    Fleming Island, Florida 32003, United States
  • Clinical Trials Research
    Lincoln, Florida 95648, United States
  • Clinical Research Group of St. Petersburgh
    Saint Petersburg, Florida 33707, United States
  • Neurotrials Research Incorporated
    Atlanta, Georgia 30342, United States
  • Sleep Practitioners, LLC
    Macon, Georgia 31210, United States
  • Hawaii Pacific Neurosciences
    Honolulu, Hawaii 96817, United States
  • Saltzer Clinical Research
    Nampa, Idaho 83686, United States
  • Rowe Neurology Institute
    Lenexa, Kansas 66214, United States
  • Sleep Disorders Center of the Mid-Atlantic
    Glen Burnie, Maryland 21061, United States
  • Neurocare Inc.
    Newton, Massachusetts 02459, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • Garden City Asthma and Sleep Center
    Garden City, New York 11530, United States
  • Research Carolina of Hickory
    Hickory, North Carolina 28601, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Clinical Trials of America - NC, LLC
    Winston-Salem, North Carolina 27103, United States
  • CTI Clinical Research II
    Cincinnati, Ohio 45212, United States
  • Ohio Sleep Medicine Institue
    Dublin, Ohio 43017, United States
  • Cleveland Sleep Research Center
    Middleburg Heights, Ohio 44130, United States
  • Robert V. Sibilia, MD, Inc.
    Wooster, Ohio 44691, United States
  • Brian Abaluck LLC
    Paoli, Pennsylvania 19301, United States
  • Wesley Neurology Clinic Pc (Multiple Sclerosis)
    Cordova, Tennessee 38018, United States
  • FutureSearch Trials of Neurology, LP
    Austin, Texas 78731, United States
  • InSite Clinical Research
    DeSoto, Texas 75115, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Texas 32216, United States
  • Dm Clinical Research / Martin Diagnostic Clinic
    Tomball, Texas 77375, United States
  • HOSPITAL AZ SINT-JAN_Neurology department
    Brugge, 8000, Belgium
  • Hospital Universitair Zieknhuis Brussel, Pneumology and Sleep Laboratory
    Brussels, 1090, Belgium
  • University Hospital Gent, Department of General Internal Medicine and Center of neurophysiological Monitoring
    Gent, 9000, Belgium
  • Hospital UZ Leuven_ Pneumology Department
    Leuven, 3000, Belgium
  • Acibadem City Clinic Tokuda Hospital EAD
    Sofia, 1407, Bulgaria
  • Canadian Phase Onward Inc.
    Toronto, Ontario M3J 2C5, Canada
  • Queensway Sleep Lab Sleep Clinic (MedSleep)- 5359 Dundas Street West, Suite 202, Etobicoke, ON M9B 1B1
    Etobicoke, M9C 5N2, Canada
  • The Medical Arts Health Research Group
    Kelowna, V1Y 3G8, Canada
  • Somni Research Inc.
    Markham, L3R 1A3, Canada
  • Somni Research, Calgary
    Toronto, M3H 3W1, Canada
  • CANADIAN PHASE ONWARD INC. (Toronto)
    Toronto, M3J 0K2, Canada
  • Narodni Ustav Dusevniho Zdravi (National Institute of Mental Health)
    Klecany, Czechia
  • Fakultní nemocnice Ostrava, Spánková laboratoř
    Ostrava-Poruba, 70852, Czechia
  • Nemocnice České Budějovice, Centrum pro poruchy spánku a spánkovou medicínu
    České Budějovice, 37087, Czechia
  • Vitalmed Uniklinikka
    Helsinki, 380, Finland
  • Oivauni Oy - Kuopio
    Kuopio, 70100, Finland
  • Oivauni Oy - Tampere
    Tampere, Finland
  • Unitutkimusyksikkö, Turun Yliopisto
    Turku, Finland
  • CHRU De Lille - Hospital Salengro - Neurophysiologie Clinique
    Lille, 59037, France
  • Clinique beau soleil - Department Sleep and Neurology
    Montpellier, France
  • CHU NIMES - Unité de Sommeil
    Nîmes, 30029, France
  • Advanced Sleep Research GmbH
    Berlin, 10117, Germany
  • Klinische Forschung Berlin-Mitte GmbH
    Berlin, 10117, Germany
  • Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin Kompetenzzentrum Schlafmedizin
    Berlin, 12200, Germany
  • Synexus Clinical Research GmbH
    Bochum, 44787, Germany
  • Klinische Forschung Dresden GmbH
    Dresden, 1069, Germany
  • Synexus Clinical Research GmbH
    Frankfurt, 60313, Germany
  • Klinische Forschung Hannover Mitte GmbH
    Hannover, 30159, Germany
  • Interdisziplinäre Schlafmedizin, Pfalzklinikum
    Klingenmünster, 76889, Germany
  • Zentrum für Integrative Psychiatrie (ZiP) Universität zu Lübeck
    Lübeck, 23538, Germany
  • Central Insitute of Mental Health Sleep laboratory Medical Faculty Mannheim/Heidelberg University
    Mannheim, 68159, Germany
  • Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie der Universität am Bezirksklinikum Regensburg
    Regensburg, 93053, Germany
  • SOMNIBENE Institut für Medizinische Forschung und Schlafmedizin Schwerin GmbH
    Schwerin, 19053, Germany
  • Magyar Honvédség Egészségügyi Központ, Neurológiai Osztály
    Budapest, 1134, Hungary
  • Somnius Kft. SomnoCenter Szeged
    Szeged, 6725, Hungary
  • Dong-A University Hospital
    Busan, 49201, Korea, Republic of
  • 4F Neuroimaging analysis laboratory, 56 Dalseong-ro, Jung-gu
    Daegu, 41931, Korea, Republic of
  • Chungnam National University Hospital
    Daejeon, 35015, Korea, Republic of
  • 3F, 2nd Building, Psychiatry Outpatient, Family Counseling Room, 42 Jebong-ro, Donggu
    Gwangju, 61469, Korea, Republic of
  • 8F Sleep Lab, 1st Building,82, Gumi-ro 173 Beon-gil, Bundang-gu
    Seongnam, 13620, Korea, Republic of
  • 3F Sleep Medicine Center, 101 Daehak-Ro Jongno-Gu
    Seoul, 3080, Korea, Republic of
  • 1st CRC room, 2F, Jejoong building, 50-1 Yonsei-ro,, Seodaemun-gu
    Seoul, 3722, Korea, Republic of
  • B2F, Clinical Trial Center, Konkuk University Medical Center 120-1, Neungdong-ro, Gwangjin-gu
    Seoul, 5030, Korea, Republic of
  • B1F Neurological examination room, 892 Dongnam-ro, Gangdong-gu
    Seoul, 5278, Korea, Republic of
  • 2F Psychiatry Outpatient, 93, Jungbu-daero, Paldal-gu
    Suwon, 16247, Korea, Republic of
  • Göteborgs Universitet, Centrum för sömn och vakenhetsstörningar
    Göteborg, 41390, Sweden
  • SOPHIAHEMMET (Stockholm)
    Stockholm, 11486, Sweden
  • Sömnutredningsmottagningen, smärtcentrum Akademiska sjukhuset
    Uppsala, 75185, Sweden
  • Universitetssjukhuset Örebro Neurokliniken, Sömnenheten
    Örebro, 70185, Sweden
09

References and documents

Publications

  • Hudgens S, Phillips-Beyer A, Newton L, Seboek Kinter D, Benes H. Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ). Patient. 2021 Mar;14(2):249-268. doi: 10.1007/s40271-020-00474-z. Epub 2020 Nov 1. PubMed 33131027 ↗
  • Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA, Pain S, Kinter DS, Roth T; investigators. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022 Feb;21(2):125-139. doi: 10.1016/S1474-4422(21)00436-1. Erratum In: Lancet Neurol. 2022 Mar;21(3):e3. doi: 10.1016/S1474-4422(22)00029-1. Lancet Neurol. 2022 Jun;21(6):e6. doi: 10.1016/S1474-4422(22)00144-2. PubMed 35065036 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Apr 2020, 22 months.

Results were first posted in Mar 2022, 1 year 11 months after primary completion. A results delay was requested in Oct 2020.

Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 22 months is above that.

Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2018
First posted
Jul 2, 2018
StartActual
May 29, 2018
Primary completionActual
Apr 9, 2020
CompletionActual
May 14, 2020
Results delay requested
Oct 20, 2020
Results first posted
Mar 25, 2022
Last update
Mar 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03575104
Responsible party
Sponsor
First posted
Jul 2, 2018
Start date
May 29, 2018
Primary completion
Apr 9, 2020
Completion
May 14, 2020
Results posted
Mar 25, 2022
Last update
Mar 25, 2022

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion